Evidence map›Paper›PMID 35655774›Full record

ArticleFrontiers in immunology2022

Hyperimmune Targeting Staphylococcal Toxins Effectively Protect Against USA 300 MRSA Infection in Mouse Bacteremia and Pneumonia Models.

Xiaobing Han, Roger Ortines, Ipsita Mukherjee, Tulasikumari Kanipakala, Thomas Kort, Shardulendra P Sherchand, Grant Liao, Mark Mednikov, Agnes L Chenine, M Javad Aman and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Xiaobing HanResearch and Development, Emergent BioSolutions Canada Inc., Winnipeg, MB, Canada.
Roger OrtinesIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
Ipsita MukherjeeIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
Tulasikumari KanipakalaIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
Thomas KortIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
Shardulendra P SherchandIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
Grant LiaoIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
Mark MednikovIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
Agnes L ChenineIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
M Javad AmanIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
Cory L NykiforukResearch and Development, Emergent BioSolutions Canada Inc., Winnipeg, MB, Canada.
Rajan P AdhikariIntegrated Biotherapeutics Inc. (IBT), Rockville, MD, United States.
Integrated BioTherapeutics (United States) · USUniversity of Manitoba · CA

Funding

ISTAb- A novel therapy to target staphylococcal toxins at the site of infectionsR43AI136143 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI ADHIKARI, RAJAN P · 2019 to 2020
$600k
NIAID NIH HHS R43 AI136143
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BacteremiaMethicillin-Resistant Staphylococcus aureusPneumoniaAnimalsImmunoglobulin GMiceRabbitsStaphylococcus aureusSuperantigensImmunoglobulin GSuperantigensbacteremia modelhyperimmuneIBT-V02-F(ab’)2IBT-V02 vaccinepneumonia modelS. aureus

Identifiers

PMID35655774
PMCPMC9152286
OpenAlexW4280582463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.